At AbsTech, our mission is to decrease patient harm and increase the therapeutic success of chemotherapies. We are developing a next-generation drug delivery platform that outperforms current solutions, enabling more effective and safer treatments for patients with solid tumours. Better Patient Outcomes: Our proprietary delivery system aims to reduce chemotherapy toxicity by up to tenfold, improving patient quality of life. Efficiency & Affordability: Designed for faster, more cost-effective development, our platform is applicable to a broad range of solid tumor treatments. Partner-Friendly: We offer attractive strategic opportunities for pharmaceutical companies looking to enhance the therapeutic index of their existing therapies. Founders: Dr. Simon Beaudoin, PhD: A biochemistry researcher, serial inventor, and entrepreneur with a proven track record in guiding therapies through clinical development. Ben Kachkowski Weiser: Expert in AI-driven computational chemistry, with startup experience in drug discovery optimization. Adam Dufour: A specialist in antibody-based therapeutics and pharmaceutical chemistry, with a history of driving early-stage biotech ventures forward. Contact for Partnerships or Investment: To learn more about partnership or investment opportunities, please reach out to adam.dufour@abstech-sci.com.
| Employees | 4 (0 on RocketReach) |
| Founded | 2024 |
| Industry | Biotechnology Research |
Looking for a particular AbsTech employee's phone or email?
AbsTech Questions
